These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 951836)

  • 21. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigations on clinico-chemical correlations in uraemic polyneuritis.
    Man NK; Cueuille G; Zingraff J; Drueke T; Jungers P; Sausse A; Billon JP; Funck-Brentano JL
    Proc Eur Dial Transplant Assoc; 1975; 11():214-21. PubMed ID: 1197256
    [No Abstract]   [Full Text] [Related]  

  • 23. [Relationship between uremia polyneuropathy, uremic glucose metabolism disorder and severity of uremic intoxication in dialysis patients].
    Goubeaud G; Kunze K; Hohmann KH; Schütterle G; Biro G
    Verh Dtsch Ges Inn Med; 1974; 80():728-31. PubMed ID: 4454650
    [No Abstract]   [Full Text] [Related]  

  • 24. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intestinal elimination of uremic metabolites by the adsorbents].
    Drüeke T
    Med Klin; 1976 Jan; 71(3):87-93. PubMed ID: 233947
    [No Abstract]   [Full Text] [Related]  

  • 27. Characterization of sub-peak b4.2, middle molecule.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():28-32. PubMed ID: 7295091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A dialyzable toxic factor in uremia.
    Lonergan ET; Semar M; Lange K
    Trans Am Soc Artif Intern Organs; 1970; 16():269-71. PubMed ID: 4318263
    [No Abstract]   [Full Text] [Related]  

  • 29. Separation and quantification of the "middle molecules" in uremia.
    Chapman GV; Ward RA; Farrell PC
    Kidney Int; 1980 Jan; 17(1):82-8. PubMed ID: 7374022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Separation of peptides of "middle" molecular weight from biological fluids of patients with uremia.
    Fürst P; Bergström J; Gordon A; Johnsson E; Zimmerman L
    Kidney Int Suppl; 1975 Feb; (3):272-5. PubMed ID: 1057698
    [No Abstract]   [Full Text] [Related]  

  • 32. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry in the search for uremic toxins.
    Niwa T
    Mass Spectrom Rev; 1997; 16(6):307-32. PubMed ID: 9703693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracorporeal strategies for the removal of middle molecules.
    Winchester JF; Audia PF
    Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid improvement of uremic neuropathy on short high-efficiency hemodialysis with special reference to middle molecules.
    Manohar NL; Gorfien PC; Namba T; Louis BM; Lipner HI
    ASAIO Trans; 1987; 33(3):274-9. PubMed ID: 3675953
    [No Abstract]   [Full Text] [Related]  

  • 36. Biochemical and clinical evidence for uremic toxicity.
    Bouré T; Vanholder R
    Artif Organs; 2004 Mar; 28(3):248-53. PubMed ID: 15046622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A method for separation of middle molecules by high performance liquid chromatography: application in studies of glucuronyl-o-hydroxyhippurate in normal and uremic subjects.
    Zimmerman L; Bergström J; Jörnvall H
    Clin Nephrol; 1986 Feb; 25(2):94-100. PubMed ID: 3698350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in the analysis of uremic toxins by mass spectrometry.
    Niwa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(25):2600-6. PubMed ID: 19083276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thioctacid in uremic polyneuropathy].
    Nassif A
    Med Welt; 1982 Dec; 33(50):1838. PubMed ID: 6820109
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical and metabolic consequences of uremic toxicity].
    Rutkowski P
    Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.